Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) is now available.
Lepu Biopharma Co., Ltd. successfully held its 2024 Annual General Meeting (AGM) on June 27, 2025, where all proposed resolutions were approved by shareholders. The resolutions included approval of financial reports, profit distribution plans, and the re-appointment of Ernst & Young as auditors, reflecting strong shareholder support and strategic alignment for the company’s future operations.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company is focused on developing and commercializing innovative medicines, with a market focus on addressing unmet medical needs.
Average Trading Volume: 24,415,556
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.58B
Find detailed analytics on 2157 stock on TipRanks’ Stock Analysis page.
Trending Articles:
- Ford Mustang Cobra Jet Fastest Electric Car on the Planet, Ford Stock (NYSE:F) Notches Up
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test